2414046-33-4

HDAC-IN-39 (compound 16c) is a potent HDAC inhibitor, with IC50 values of 1.07 μM (HDAC1), 1.47 μM (HDAC2), and 2.27 μM (HDAC3), respectively. HDAC-IN-39 also significantly inhibits microtubule polymerization. HDAC-IN-39 induces cell cycle arrest at the G2/M phase. HDAC-IN-39 displays promising anticancer activity against resistant cancer cells[1].

HDAC1: 1.07 μM (IC₅₀); HDAC2: 1.47 μM (IC₅₀); HDAC3: 2.27 μM (IC₅₀); HDAC8: >10 μM (IC₅₀)

[1] Wu WC, et al. Design, synthesis, and evaluation of N-phenyl-4-(2-phenylsulfonamido)-benzamides as microtubule-targeting agents in drug-resistant cancer cells, displaying HDAC inhibitory response. Eur J Med Chem. 2020 Apr 15;192:112158. DOI:10.1016/j.ejmech.2020.112158